Search research articles
Contact Us
Filters
Showing results (51-60 of 565) with videos related to
Page
of 57
Sort By:
Journal of Thoracic Disease
|
May 25, 2026
Chemotherapy in combination with KRAS inhibitors in <i>KRAS</i>-mutated non-small cell lung cancer
Rafael Rosell, María González-Cao
The Lancet. Oncology
|
October 9, 2019
Are neutralising anti-VEGF or VEGFR2 antibodies necessary in the treatment of EGFR-mutated non-small-cell lung cancer?
Rafael Rosell, Carlos Pedraz-Valdunciel
Journal of Thoracic Disease
|
April 30, 2015
Second-line treatment in EGFR-unselected patients: is it time to close one arm of this river's DELTA?
Daniela Morales-Espinosa, Rafael Rosell
The Lancet Regional Health. Europe
|
September 5, 2022
Ablating lung cancer, knowing the tumor better
Rafael Rosell, María González-Cao
JTO Clinical and Research Reports
|
October 16, 2023
Lung Cancer Organoids as Avatars of Patients With Lung Cancer in the Prediction of Therapeutic Response
Rafael Rosell, Carlos Pedraz-Valdunciel
Lung Cancer (Amsterdam, Netherlands)
|
February 9, 2005
Neoadjuvant treatment of early-stage resectable non-small-cell lung cancer
Daniel C Betticher, Rafael Rosell
Nature Reviews. Clinical Oncology
|
December 6, 2023
Chemotherapy in EGFR-mutated NSCLC: optimizing combinations with TKIs and amivantamab
Rafael Rosell, María González-Cao
Lancet (London, England)
|
February 14, 2021
Cemiplimab monotherapy in advanced non-squamous and squamous non-small cell lung cancer
Rafael Rosell, Maria Gonzalez-Cao
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 13, 2007
Weighing tumor biology in treatment decisions for patients with non-small cell lung cancer
Frances A Shepherd, Rafael Rosell
Translational Lung Cancer Research
|
January 23, 2016
Cancer stem cells and immunoresistance: clinical implications and solutions
Jordi Codony-Servat, Rafael Rosell
Page
of 57
Search research articles
Search
Showing results (51-60 of 565) with videos related to
Sort By:
Page
of 57
Journal of Thoracic Disease
|
May 25, 2026
Chemotherapy in combination with KRAS inhibitors in <i>KRAS</i>-mutated non-small cell lung cancer
Rafael Rosell, María González-Cao
The Lancet. Oncology
|
October 9, 2019
Are neutralising anti-VEGF or VEGFR2 antibodies necessary in the treatment of EGFR-mutated non-small-cell lung cancer?
Rafael Rosell, Carlos Pedraz-Valdunciel
Journal of Thoracic Disease
|
April 30, 2015
Second-line treatment in EGFR-unselected patients: is it time to close one arm of this river's DELTA?
Daniela Morales-Espinosa, Rafael Rosell
The Lancet Regional Health. Europe
|
September 5, 2022
Ablating lung cancer, knowing the tumor better
Rafael Rosell, María González-Cao
JTO Clinical and Research Reports
|
October 16, 2023
Lung Cancer Organoids as Avatars of Patients With Lung Cancer in the Prediction of Therapeutic Response
Rafael Rosell, Carlos Pedraz-Valdunciel
Lung Cancer (Amsterdam, Netherlands)
|
February 9, 2005
Neoadjuvant treatment of early-stage resectable non-small-cell lung cancer
Daniel C Betticher, Rafael Rosell
Nature Reviews. Clinical Oncology
|
December 6, 2023
Chemotherapy in EGFR-mutated NSCLC: optimizing combinations with TKIs and amivantamab
Rafael Rosell, María González-Cao
Lancet (London, England)
|
February 14, 2021
Cemiplimab monotherapy in advanced non-squamous and squamous non-small cell lung cancer
Rafael Rosell, Maria Gonzalez-Cao
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 13, 2007
Weighing tumor biology in treatment decisions for patients with non-small cell lung cancer
Frances A Shepherd, Rafael Rosell
Translational Lung Cancer Research
|
January 23, 2016
Cancer stem cells and immunoresistance: clinical implications and solutions
Jordi Codony-Servat, Rafael Rosell
Page
of 57